Pfizer Biopharma sales grew 3% on a reported basis (up 7% an operational basis) from the year-ago period to $9.19 billion. Higher sales of Eliquis, Ibrance, Prevnar 13/Prevenar 13 and Xeljanz drove this segment's sales growth.